Cargando…
肿瘤突变负荷对肺癌免疫治疗疗效的预测价值
The morbidity and mortality of lung cancer is the first in the world, immunotherapy has become a important treatment strategy in addition to chemotherapy, radiotherapy and targeted therapy. In recent years, the US Food and Drug Administration (FDA) has successively approved immunological checkpoint...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580077/ https://www.ncbi.nlm.nih.gov/pubmed/31196372 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.06.08 |
Ejemplares similares
-
肿瘤突变负荷应用于肺癌免疫治疗的专家共识
Publicado: (2021) -
小细胞肺癌免疫治疗疗效预测指标的现状与未来
Publicado: (2020) -
非小细胞肺癌中EGFR基因状态的检测对EGFR-TKIs疗效的预测价值
Publicado: (2010) -
非小细胞肺癌患者的肿瘤突变负荷异质性研究进展
Publicado: (2021) -
非小细胞肺癌新辅助免疫治疗的研究进展、获益人群、治疗周期和疗效预测
Publicado: (2022)